BIOSIG TECHNOLOG. DL-,001 Logo
US09073N2018
A2N5TW
BSGM

BIOSIG TECHNOLOG. DL-,001

Forecast

The analysts' average price target is €0.37 (-92.24%). The median is €0.37 (-92.24%).

Buy
  2
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • BioSig Technologies renamed Streamex Corp after merger and gets new ticker symbol STEX

    BioSig Technologies will change its name to Streamex Corp. effective September 12, 2025, following its merger with Streamex Exchange Corporation, and will change its Nasdaq ticker from BSGM to STEX; shareholders do not need to take any action and the CUSIP remains unchanged. The company completed a committed capital raise of about $15 million by selling 3,852,149 common shares at $3.90 per share and intends to use the net proceeds, among other things, to purchase gold bars and for working capital. Authorized common shares were increased from 200 million to 500 million, and through its subsidiary Streamex the company entered a three‑year exclusive partnership with Monetary Metals to tokenize yield‑bearing gold products. Apart from the rebranding, the structure and operating business are to remain unchanged. » More on de.investing.com


  • Streamex teams up with Monetary Metals for tokenized gold product with up to 4% yield

    Streamex, a subsidiary of BioSig, obtained exclusive three-year rights to tokenize interest-bearing gold products from Monetary Metals and access to its leasing and bond programs. Investors could therefore earn annual returns of up to 4% on tokenized gold bar products; Streamex will finance at least 10% of the qualifying gold-leasing contracts and receive a revenue-linked share. BioSig also raised about USD 15 million through a public offering, will purchase gold bars and is using the capital increase, while InvestingPro points to weak financial metrics and short-term liquidity shortages. » More on de.investing.com


  • BioSig Technologies: shareholders approve share increase and new board structure

    Shareholders of BioSig Technologies voted to increase the authorized common shares from 200 million to 500 million and approved an increase to the long-term incentive plan. They also approved measures to issue common shares and convertible debt in connection with Yorkville and the classification of the board of directors into three classes with staggered three-year terms. The vote on the issuance of about 109,070,079 common shares and one super-voting preferred share related to the Streamex acquisition was deferred pending Nasdaq approval; the meeting will resume on September 26. In addition, BioSig completed an underwritten offering of roughly $15 million and restructured convertible notes with YA II PN, Ltd. (two secured convertible notes of $25 million each, with the option to expand to $50 million). » More on de.investing.com


  • Solana gains major boost as BioSig Technologies tokenizes $1.1 billion in gold on its blockchain

    BioSig Technologies will tokenize up to $1.1 billion in physical gold bullion on the Solana blockchain, significantly increasing Solana's real-world asset footprint. This move highlights Solana's technical strengths, such as low fees and high transaction speeds, and positions it as a leader in the growing asset tokenization trend. The development is seen as a strong validation of Solana's capabilities and a potential catalyst for further growth. » More on finance.yahoo.com


  • BioSig Technologies expands Streamex advisory team with Russell Starr and secures growth financing

    BioSig Technologies has appointed Russell Starr as a strategic advisor for its subsidiary Streamex Exchange Corporation to advance the tokenization of gold reserves and infrastructure. The company also secured up to $1.1 billion in growth financing to support its gold-backed treasury strategy and expanded its advisory team with additional industry experts. Analysts view the stock positively due to the new strategy and potential market returns, despite the company's continued weak financial position. » More on de.investing.com

Financials

In the last quarter, BIOSIG TECHNOLOG. DL-,001 had revenue of €0 and net profit of -€13.28m

(EUR) September 2025
YoY
Revenue 0 -
Gross profit 0 -
Net profit -13.28m -
EBITDA -12.66m -

Fundamentals

Metric Value
Market capitalization
€174.19m
Number of shares
31.33m
52-week high/low
€12.86 - €0.21
Dividends No
Beta
1.82
P/E ratio
-0.03
PEG ratio
0.00
P/B ratio
0.42
P/S ratio
121.85

Company profile

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

Name
BIOSIG TECHNOLOG. DL-,001
CEO
Anthony Amato
Headquarters Los Angeles, ct
USA
Website
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO
31/10/2014
Employees 5

Ticker symbols

Exchange Symbol
NASDAQ
BSGM
🍪

Parqet  uses cookies. Learn more